Prognostic role of FUT8 expression in relation to p53 status in stage II and III colorectal cancer

Noda, Masaru; Okayama, Hirokazu; Kofunato, Yasuhide; Chida, Shun; Tada, Takeshi; Ashizawa, Mai; Nakajima, Takahiro; Aoto, Keita; Kikuchi, Tomohiro; Sakamoto, Wataru; Endo, Hisahito; Fujita, Shotaro; Saito, Motonobu; Momma, Tomoyuki; Ohki, Shinji; Kono, Koji

doi:10.1371/journal.pone.0200315

Cited by 34 publications

(18 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have evaluated variety of genetic changes that appear to influence the prognosis of CRC patients, including microsatellite instability (MSI), RAS mutation, BRAF mutation, the human epidermal growth factor receptor 2 gene (HER2) (De Roock et al, 2010;Liu et al, 2017Liu et al, , 2018Noda et al, 2018;Salvia, Lopez-Gomez & Garcia-Carbonero, 2018). HER2 gene, which is located on chromosome 17q21, is a tyrosine kinase receptor and encodes for a 185-kDa transmembrane protein (Salvia, Lopez-Gomez & Garcia-Carbonero, 2018).…”

Section: Introductionmentioning

confidence: 99%

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

Zhang

Wang

et al. 2020

PeerJ

View full text Add to dashboard Cite

Objective To investigate the frequency and prognostic role of the human epidermal growth factor receptor 2 gene (HER2) and BRAF V600E gene mutation in Chinese patients with colorectal cancer (CRC). Methods Clinicopathological and survival information from 480 patients with stage I–III CRC were reviewed and recorded. HER2 amplification was analyzed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), BRAF V600E mutation was tested by IHC and Sanger sequencing. The relationship between HER2 and BRAF V600E mutation status and clinicopathological characteristics and outcomes were determined. Results The amplification of HER2 and BRAF V600E mutation were identified in 27 of 480 (5.63%) and 19 of 480 (3.96%) CRC patients, respectively. HER2 amplification significantly correlated with greater bowel wall invasion (P = 0.041) and more advanced TNM stage (I vs. II vs. III; 0 vs 5.78% vs. 7.41%, P = 0.013). Patients suffering from tumors with poor differentiation had a higher incidence rate of BRAF V600E mutation than those with moderate/well differentiation (7.77% vs 2.92%, P = 0.04). HER2 amplification was an independent prognostic factor for worse disease-free survival (DFS) (HR = 2.53, 95% CI: 1.21–5.30, P = 0.014). Conclusion The prevalence of HER2 amplification and BRAF V600E mutation in stage I–III CRC patients in Chinese was 6% and 4%, respectively, and HER2 amplification appeared to be associated with a worse DFS. More comprehensive molecular classification and survival analysis are needed to validate our findings.

show abstract

Section: Introductionmentioning

confidence: 99%

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

Zhang

Wang

et al. 2020

PeerJ

View full text Add to dashboard Cite

show abstract

“…Soreide et al (37) reported that cell cycle and apoptosis are associated with the prognosis of CRC. Numerous studies have reported a relationship between P53 and the development of CRC (38–40). However, to the best of our knowledge, the functional correlations of DNA repair, cell cycle, apoptosis and P53 with CXCL3 have not been previously reported.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and prognostic values of C‑X‑C motif chemokine ligand 3 in patients with colon cancer

et al. 2019

View full text Add to dashboard Cite

The diagnostic and prognostic mechanisms of C-X-C motif chemokine ligand 3 (CXCL3) in colon cancer (CC) have not yet been reported. Therefore, the objective of the present study was to use cohorts of patients from Guangxi Medical University and the Gene Expression Omnibus (GEO) database to investigate and validate CXCL3 for the diagnosis and prognosis of CC, and to explore its prospective molecular mechanism. Reverse transcription-quantitative PCR (RT-qPCR) analysis of 38 paired tumor and non-tumor tissues, and immunohistochemistry (IHC) of 212 tumor and 46 non-tumor tissues was conducted to explore the expression of CXCL3 and its diagnostic and prognostic significance in the Guangxi Medical University CC cohort. A GEO dataset, GSE40967, was used to validate the prognostic significance of CXCL3. Gene set enrichment analysis (GSEA) was also conducted to explore the potential molecular mechanisms underlying the effects of CXCL3 in CC. The RT-qPCR results indicated that CXCL3 expression was significantly higher in cancer tissues compared with adjacent normal tissues, suggesting that it may have high diagnostic value for CC. Multivariate Cox analysis based on the IHC results suggested that there was no appreciable association between CXCL3 positivity and the overall survival (OS) time of CC. However, a stratified analysis revealed that high expression of CXCL3 was associated with considerably increased mortality in the subgroup of CC patients with tumor size <5 cm (adjusted P=0.042, adjusted HR=2.298, 95% CI=1.030–5.126) and with tumor thrombus (adjusted P=0.019, adjusted HR=5.096, 95% CI=1.306–19.886). In the GSE40967 dataset, high expression of CXCL3 was closely associated with poor OS in CC (adjusted P=0.049, adjusted HR=1.416, 95% CI=1.002–2.003). Furthermore, GSEA indicated that the high expression of CXCL3 was closely associated with DNA repair, cell cycle process, cell apoptosis process and the P53 regulation pathway. In summary, these result suggest that CXCL3 might serve as a novel biomarker in the diagnosis and prognosis of CC.

show abstract

“…Known p53-positive cases were used as positive external controls for p53 immunostaining. Cases with at least 10% of the tumor cells exhibiting nuclear p53 staining were considered positive 25…”

Section: Methodsmentioning

confidence: 99%

<p>Pathological risk factors for lymph node metastasis in patients with submucosal invasive colorectal carcinoma</p>

Zhang

Wang

Huang

et al. 2019

CMAR

View full text Add to dashboard Cite

BackgroundRisk grade assessment determines therapy in patients with submucosal invasive colorectal carcinoma (CRC). However, treatment decisions are often difficult due to a lack of consensus on which risk factors should be considered. We aimed to identify predictive risk factors for lymph node metastasis (LNM) in a large cohort of submucosal invasive CRC patients from China.Patients and methodsFollowing collection of clinicopathological data and disease-free survival (DFS) rates from 290 patients who underwent radical intestinal resection with regional lymphadenectomy, we immunohistochemically assessed expression of DNA mismatch repair (MMR) proteins and p53. The correlation between clinicopathological parameters, MMR expression, p53 status, and LNM status was determined using chi-squared tests and logistic analysis. Receiver operator characteristic curve analysis was used to compare the predictive values. The DFS curves were plotted using the Kaplan–Meier method.ResultsLNM was detected in 15.5% of the cases (45/290 patients). Three pathological characteristics, high tumor differentiation grade, lymphovascular invasion (LVI), and tumor budding, were all positively related to LNM in univariate and multivariate analyses (P<0.05). MMR status did not correlate with either LNM or the pathological characteristics (P>0.05). Overexpression of p53 was associated with tumor budding status (P=0.036). With a negative predicative value of 0.92 and area under the curve of 0.76 (95% CI: 0.68–0.85), the combination of these three factors provided optimal predictive ability. Patients with all three risk factors had poorer DFS (P<0.001).ConclusionHigh tumor grade, LVI, and positive tumor budding serve as useful LNM predictors in submucosal invasive CRC.

show abstract

Prognostic role of FUT8 expression in relation to p53 status in stage II and III colorectal cancer

Cited by 34 publications

References 39 publications

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

Diagnostic and prognostic values of C‑X‑C motif chemokine ligand 3 in patients with colon cancer

<p>Pathological risk factors for lymph node metastasis in patients with submucosal invasive colorectal carcinoma</p>

Contact Info

Product

Resources

About